SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0000950170-23-033010 from Aptevo Therapeutics Inc. (APVO)

Aptevo Therapeutics Inc.
Date: July 14, 2023 · CIK: 0001671584 · Accession: 0000950170-23-033010

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-273067

Date
July 14, 2023
Author
Marvin L. White
Form
CORRESP
Company
Aptevo Therapeutics Inc.

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Mr. Daniel Crawford Re: Aptevo Therapeutics Inc. Registration Statement on Form S-1 File No. 333-273067

Dear Mr. Crawford:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-273067) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 5:30 p.m., Eastern Time, on July 18, 2023 or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704.

Very truly yours,
Aptevo Therapeutics Inc.

Show Raw Text
CORRESP
1
filename1.htm

  CORRESP

  July 14, 2023

  VIA EDGAR

  United States Securities and Exchange Commission

  Division of Corporation Finance

  Office of Life Sciences

  100 F Street, N.E.

  Washington, D.C. 20549

  Attention: Mr. Daniel Crawford

  Re: Aptevo Therapeutics Inc.

  Registration Statement on Form S-1
File No. 333-273067

  Dear Mr. Crawford:

  In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-273067) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 5:30 p.m., Eastern Time, on July 18, 2023 or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704.

  Very truly yours,

  Aptevo Therapeutics Inc.

  By: /s/ Marvin L. White

  Marvin L. White

  President and Chief Executive Officer

    CC:

    SoYoung Kwon, Aptevo Therapeutics Inc.
Daphne Taylor, Aptevo Therapeutics Inc.
Sean M. Donahue, Paul Hastings LLP